No usar medidas terapéuticas intensivas para conseguir una reducción de HbA1<7,5% en ancianos con multimorbilidad, frágiles, dependientes y con una expectativa de vida <10 años.

Sinclair A, Morley JE, Rodríguez- Manas L et al. Diabetes Mellitus in older people: position statement on behalf of the International Association of Gerontology and Geriatrics (IAGG), The European Diabetes Working Party for Older People (EDWPOP), and the International Task Force of Experts in Diabetes. J Am Med Dir Assoc 2012;13:497-502.

Inzucchi SE, Bergenstal RM, Buse JB et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: Position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364-1379.

Department of Veterans Affairs and Department of Defense [Accessed January 9,2013]. Clinical Practice guideline for the management of diabetes mellitus(on-line).Available at http://guidelines.gov/content.aspx?id=24192

Dunning T, Sinclair A, Colagiuri S. New IDF Guideline for managing type 2 diabetes in older people. http://www.idf.org/sites7default/files/attachments/DV59-1_Dunning_EN.pdf

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassaï B, Erpeldinger S, Wright JM, Gueyffier F, Cornu C. Effect of intensive glucose lowering treatment on all cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomised controlled trials. BMJ 2011;343:d4169. doi:10.1136/bmj.d4169

Hemmingsen B, Lund SS, Gluud C, Vaag A, Almdal T, Hemmingsen C, Wetterslev J. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. Cochrane Database Syst Rev 2011 Jun 15;(6).CD008143. doi:10.1002/14651858.CD008143.pub2